Resultados: 56

FANTOM II Trial: safety and performance study of the fantom sirolimus-eluting bioresorbable coronary scaffolddfirst report: 4-year clinical outcomes

J. Am. Coll. Cardiol; 76 (17 suppl. b), 2020
BACKGROUND The primary objective of the FANTOM II (Safety and Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold) was to evaluate the safety and performance of native coronary artery stenting using the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold by assessing th...

Desempenho diagnóstico da reserva de fluxo fracionado por tomografia na detecção de estenoses coronárias hemodinamicamente significativas

ABC., imagem cardiovasc; 33 (3), 2020
BACKGROUND: Coronary computed tomography angiography is a noninvasive anatomic test for the diagnosis of coronary artery disease. The coronary fractional flow reserve is the gold standard method to determine if coronary stenosis is hemodynamically significant but requires an invasive procedure. Fractiona...

Positioning on adult echocardiographic indications - 2019

ABC., imagem cardiovasc; 32 (4), 2019

Safety and clinical performance of a drug eluting absorbable metal scaffold in the treatment of subjects with de novo lesions in native coronary arteries: Pooled 12-month outcomes of BIOSOLVE-II and BIOSOLVE-III

OBJECTIVES: Based on outcomes of the BIOSOLVE-II study, a novel second generation drug eluting absorbable metal scaffold gained CE-mark in 2016. The BIOSOLVE-III study aimed to confirm these outcomes and to obtain additional 12-month angiographic data. BACKGROUND: Bioresorbable scaffolds are intended to ...

Hemodynamic analysis of a novel bioresorbable scaffold in porcine coronary artery model

BACKGROUND: The shear stress distribution assessment can provide useful insights for the hemodynamic performance of the implanted stent/scaffold. Our aim was to investigate the effect of a novel bioresorbable scaffold, Mirage on local hemodynamics in animal models. METHOD: The main epicardial coronary ar...

Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial

Lancet; 391 (10117), 2018
SUMMARY BACKGROUND Patients with peripheral artery disease have an increased risk of cardiovascular morbidity and mortality. Antiplatelet agents are widely used to reduce these complications. METHODS This was a multicentre, double-blind, randomised placebo-controlled trial for which patients were recruit...